Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David A. Wilcox
Medical College of Wisconsin, Department: Pediatrics
Should you be removed from our database? Contact us at [email protected]. Read more below.
Platelet Targeted Therapeutics, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The investigator is the co-inventor and President of the company providing the technology to be tested in the research project.
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies
PROJECT NARRATIVE Hemophilia A (HA) is an inherited bleeding disorder affecting ?1:10,000 people worldwide due to molecular-genetic defects on the X-chromosome that cause a deficiency of coagulation factor VIII (FVIII). HA is currently treated with a continuous infusion of plasma protein replacement therapy that is ineffective in ?30% of HA patients who make inhibitory antibodies (PWIA) that completely neutralize plasma FVIII. To address this serious public health issue, we propose to utilize a novel strategy in a Phase I Clinical Trial for long-term correction of severe HA in PWIA with hematopoietic stem cell gene therapy that produces genetically engineered human blood platelets that synthesize, store, and secrete FVIII directly at the site of a vascular injury to repair blood vessels without alerting the immune system. 1
Filed on June 06, 2019.
Tell us what you know about David A. Wilcox's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
David A. Wilcox filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David A. Wilcox | Medical College of Wisconsin | Conflict of Interest | Platelet Targeted Therapeutics, LLC | $5,000 - $9,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.